| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
27,800,000 |
| Market
Cap: |
1.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.063 - $0.063 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ContraFect is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s primary product candidate, exebacase, for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis. In addition to bacteremia, Staphylococcus aureus is also a common cause of pneumonia and osteomyelitis as well as biofilm-associated infections of heart valves, indwelling devices and catheters. Co.'s product candidate, CF-370, is designed to target a gram -negative bacteria including Pseudomonas aeruginosa.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-09-22 |
4 |
AS |
$4.76 |
$13,644 |
D/D |
(2,867) |
10,773 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-09-08 |
4 |
AS |
$4.90 |
$14,057 |
D/D |
(2,867) |
14,340 |
|
- |
|
| Gregory Julia P |
CEO |
• – – |
2015-03-02 |
4 |
B |
$4.61 |
$54,297 |
D/D |
11,778 |
50,283 |
2.74 |
- |
|
| Wittekind Michael G. |
Chief Scientific Officer |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$71,572 |
D/D |
17,893 |
17,893 |
|
- |
|
| Messinger Michael |
VP Finance |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$53,164 |
D/D |
13,291 |
13,291 |
|
- |
|
| Gregory Julia P |
CEO |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$119,784 |
D/D |
29,946 |
38,505 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$68,828 |
D/D |
17,207 |
17,207 |
|
- |
|
| Huang David B. |
Chief Medical Officer |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$95,604 |
D/D |
23,901 |
23,901 |
|
- |
|
| Dong Nancy |
VP Controller |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$25,148 |
D/D |
6,287 |
15,161 |
|
- |
|
| Kappel Barry J. |
SVP Business Development |
• – – |
2014-09-11 |
4 |
A |
$4.00 |
$50,128 |
D/D |
12,532 |
12,532 |
|
- |
|
| Ernest W Moody Revocable Trust |
10% Owner |
– – • |
2014-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000,000 |
|
- |
|
| Zan Shengda |
Director |
– • – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,337,036 |
|
- |
|
| Dong Nancy |
VP ControllerOfficer |
• – – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,874 |
|
- |
|
| Huang David B. |
Chief Medical OfficerOfficer |
• – – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,568 |
|
- |
|
| Gregory Julia P |
CEOOfficer |
• – – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,559 |
|
- |
|
| Blech Isaac |
Director |
– • – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,280,805 |
|
- |
|
| Barer Sol J |
Director |
– • – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
775,933 |
|
- |
|
| Scheinberg David A |
Director |
– • – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,770 |
|
- |
|
| Nowinski Robert C. |
10% Owner |
– – • |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
189,671 |
|
- |
|
| Low David N. |
Director |
– • – |
2014-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,550 |
|
- |
|
45 Records found
|
|
Page 2 of 2 |
|
|
